Microglia inhibitor stops neuronal cell death after TBI
Researchers at Trinity College in Dublin have demonstrated that resetting brain-specific immune cells improves traumatic brain injury (TBI) recovery.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Post-Brexit budget drives cuts in Horizon Europe
/in News/by Thomas GabrielczykNegotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM acquires Glycom A/S for 765m
/in News/by Thomas GabrielczykRoyal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2-fucosyl lactose, Danish Glycom A/S.
Immatics Biotechnologies lands 1.1bn deal with GSK
/in News/by Thomas GabrielczykUS-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.
KKR backs Belgian tech provider Univercells SA
/in News/by Thomas GabrielczykUnivercells S.A. cashes in up to 50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.
EU diagnostic labs prepared for Sars-CoV-2
/in News/by Thomas GabrielczykShortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic.
PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug
/in News/by Thomas GabrielczykPharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer).
Diabetes combo improves regeneration of beta cells
/in News/by Thomas GabrielczykUsing a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas.
JAKPot for treating bone loss
/in News/by Thomas GabrielczykResearchers report that JAK inhibitors a class of approved anti-inflammatory drugs prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
Mereo BioPharma raise money to back Phase III trials
/in News/by Thomas GabrielczykMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.